{ "run": { "id": "cmnr152bi0636p658t138gcz0", "region": "US", "assetId": "cmnr152b10632p658vhriywte", "ticker": "RVTY", "snapshotId": "cmnr152b60634p658ryso3mug", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:46.491Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr152b60634p658ryso3mug", "assetId": "cmnr152b10632p658vhriywte", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 91.44, "price": 90.4, "dayLow": 89.65, "volume": 1188204, "dayHigh": 92.99, "currency": "USD", "prevClose": 87.79, "week52Low": 81.36, "week52High": 118.2999 }, "fundamentals": { "pe": 46.9130434782609, "beta": 1.02127810919278, "epsTTM": 2.07, "fcfTTM": 180561000, "growth": { "epsYoy": -0.06334841628959281, "revenueYoy": 0.03666934540726657 }, "sector": "Laboratory Analytical Instruments", "margins": { "net": 0.1718627993895807, "gross": 0.6008263729149694, "operating": 0.2242569196049788 }, "website": "http://revvity.com", "industry": "Biotechnology", "pegRatio": -7.40555900621117, "ebitdaTTM": 866249000, "forwardPe": 17.9500924214418, "marketCap": 12871238120, "totalCash": 919860000, "totalDebt": 3220064000, "debtEquity": 0.444124705531863, "quickRatio": 1.278906377934657, "revenueTTM": 3311822000, "companyName": "REVVITY, INC.", "priceToBook": 1.5609423007961, "currentRatio": 1.682444116264011, "dividendYield": null, "returnOnAssets": 0.04677512947253343, "returnOnEquity": 0.0332674515472335, "analystOpinions": null, "businessSummary": "Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.", "enterpriseValue": 13617597620, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 11000, "sharesOutstanding": 111799374, "enterpriseToEbitda": 15.72018856010223, "analystTargetMedian": null, "enterpriseToRevenue": 4.111814469497455, "operatingCashflowTTM": 582933000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:46.482Z" }, "results": [ { "id": "cmnr152bk0638p6587a5yzw3n", "runId": "cmnr152bi0636p658t138gcz0", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"RVTY\",\"currency\":\"USD\",\"current_price\":90.4,\"target_price_6m\":96.5,\"target_price_12m\":101,\"recommendation\":\"BUY\",\"confidence\":0.58,\"thesis_bullets\":[\"Life sciences end-market recovery supports mid-single-digit revenue growth\",\"Forward PE of ~18x implies significant earnings ramp already priced in\",\"Gross margins above 60% provide operating leverage on incremental revenue\",\"Elevated net debt of $2.3B constrains financial flexibility near-term\",\"Trading near 52-week low offers reasonable entry if recovery materializes\"],\"key_drivers\":[{\"driver\":\"Biotech/pharma R&D spending recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion from post-transformation operational leverage\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Gene/cell therapy market growth driving instrument demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt levels limiting capital deployment flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"EPS declining YoY (-6.3%) signals near-term earnings pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong gross margin profile (60%) supports pricing power\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Macro uncertainty affecting biotech funding environment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FCF conversion notably lower than operating cash flow\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Prolonged biotech funding winter delays customer capex recovery\",\"Debt refinancing risk if rates stay elevated\",\"Competitive pressure in diagnostics from larger players\",\"Tariff or trade policy disruptions to global supply chain\",\"Forward earnings expectations miss, causing multiple compression\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.25,\"wacc\":0.092,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":76,\"prob\":0.2,\"notes\":\"Life sciences recovery stalls; earnings miss forward estimates, multiple contracts to 15x.\"},\"base\":{\"target_price\":101,\"prob\":0.55,\"notes\":\"Moderate recovery with revenue growth ~5%, margins expand toward 25%, ~18x forward PE.\"},\"bull\":{\"target_price\":122,\"prob\":0.25,\"notes\":\"Strong biopharma spending rebound, margin expansion, multiple re-rates to 21x forward PE.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA approach. Forward EPS ~$5.04 implied by snapshot forward PE of 17.95x. Base case assumes ~$5.60 NTM EPS in 12M at 18x multiple. Trailing PE/forward PE gap signals expected earnings inflection. Weighted scenario price ~$101 consistent with base. Mixed evidence (declining EPS YoY, moderate revenue growth, but attractive forward valuation) keeps confidence moderate. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Prolonged biotech funding winter delays customer capex recovery", "Debt refinancing risk if rates stay elevated", "Competitive pressure in diagnostics from larger players", "Tariff or trade policy disruptions to global supply chain", "Forward earnings expectations miss, causing multiple compression" ], "ticker": "RVTY", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Moderate recovery with revenue growth ~5%, margins expand toward 25%, ~18x forward PE.", "target_price": 101 }, "bear": { "prob": 0.2, "notes": "Life sciences recovery stalls; earnings miss forward estimates, multiple contracts to 15x.", "target_price": 76 }, "bull": { "prob": 0.25, "notes": "Strong biopharma spending rebound, margin expansion, multiple re-rates to 21x forward PE.", "target_price": 122 } }, "confidence": 0.58, "assumptions": { "wacc": 0.092, "revenue_cagr_3y": 0.055, "terminal_multiple": 18, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Biotech/pharma R&D spending recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion from post-transformation operational leverage", "impact": "HIGH", "direction": "POS" }, { "driver": "Gene/cell therapy market growth driving instrument demand", "impact": "MED", "direction": "POS" }, { "driver": "Elevated debt levels limiting capital deployment flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "EPS declining YoY (-6.3%) signals near-term earnings pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Strong gross margin profile (60%) supports pricing power", "impact": "MED", "direction": "POS" }, { "driver": "Macro uncertainty affecting biotech funding environment", "impact": "HIGH", "direction": "NEG" }, { "driver": "FCF conversion notably lower than operating cash flow", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended forward PE and EV/EBITDA approach. Forward EPS ~$5.04 implied by snapshot forward PE of 17.95x. Base case assumes ~$5.60 NTM EPS in 12M at 18x multiple. Trailing PE/forward PE gap signals expected earnings inflection. Weighted scenario price ~$101 consistent with base. Mixed evidence (declining EPS YoY, moderate revenue growth, but attractive forward valuation) keeps confidence moderate. Not investment advice.", "current_price": 90.4, "recommendation": "BUY", "thesis_bullets": [ "Life sciences end-market recovery supports mid-single-digit revenue growth", "Forward PE of ~18x implies significant earnings ramp already priced in", "Gross margins above 60% provide operating leverage on incremental revenue", "Elevated net debt of $2.3B constrains financial flexibility near-term", "Trading near 52-week low offers reasonable entry if recovery materializes" ], "target_price_6m": 96.5, "target_price_12m": 101 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35889, "createdAt": "2026-04-09T05:21:46.491Z", "usage": { "inputTokens": 3587, "outputTokens": 1604, "costUsd": 0.058035 } }, { "id": "cmnr152bk063bp65868xtoac1", "runId": "cmnr152bi0636p658t138gcz0", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity_Research_AI_Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"RVTY\",\n \"currency\": \"USD\",\n \"current_price\": 90.4,\n \"target_price_6m\": 95,\n \"target_price_12m\": 99,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Strong position in growing cell/gene therapy markets.\",\n \"High gross margins support profitability and cash flow.\",\n \"Forward P/E suggests earnings recovery ahead.\",\n \"Manageable debt levels with good liquidity ratios.\",\n \"Valuation offers reasonable upside with balanced risks.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Growth in biotech R&D spending\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Adoption of new cell/gene therapies\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive pressures in diagnostics\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory approvals for products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Earnings volatility from market cycles\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Market sentiment towards biotech sector\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Operational efficiency improvements\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Economic downturn reducing pharmaceutical R&D budgets\",\n \"Technological disruption in laboratory instruments\",\n \"Increased competition from larger diagnostic companies\",\n \"Regulatory changes delaying product launches\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.24,\n \"wacc\": 0.09,\n \"terminal_multiple\": 12.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 80, \"prob\": 0.2, \"notes\": \"Slower growth and multiple contraction due to competition.\" },\n \"base\": { \"target_price\": 99, \"prob\": 0.6, \"notes\": \"Steady execution and market growth driving earnings.\" },\n \"bull\": { \"target_price\": 110, \"prob\": 0.2, \"notes\": \"Accelerated adoption and margin expansion boosting valuation.\" }\n },\n \"method_notes\": \"Valuation based on forward earnings and industry multiples. BUY due to ~9% 12M upside with medium confidence from mixed growth signals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Equity_Research_AI_Model", "risks": [ "Economic downturn reducing pharmaceutical R&D budgets", "Technological disruption in laboratory instruments", "Increased competition from larger diagnostic companies", "Regulatory changes delaying product launches" ], "ticker": "RVTY", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution and market growth driving earnings.", "target_price": 99 }, "bear": { "prob": 0.2, "notes": "Slower growth and multiple contraction due to competition.", "target_price": 80 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption and margin expansion boosting valuation.", "target_price": 110 } }, "confidence": 0.65, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 12, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Growth in biotech R&D spending", "impact": "HIGH", "direction": "POS" }, { "driver": "Adoption of new cell/gene therapies", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pressures in diagnostics", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approvals for products", "impact": "HIGH", "direction": "POS" }, { "driver": "Earnings volatility from market cycles", "impact": "MED", "direction": "NEG" }, { "driver": "Market sentiment towards biotech sector", "impact": "MED", "direction": "POS" }, { "driver": "Operational efficiency improvements", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on forward earnings and industry multiples. BUY due to ~9% 12M upside with medium confidence from mixed growth signals. Not investment advice.", "current_price": 90.4, "recommendation": "BUY", "thesis_bullets": [ "Strong position in growing cell/gene therapy markets.", "High gross margins support profitability and cash flow.", "Forward P/E suggests earnings recovery ahead.", "Manageable debt levels with good liquidity ratios.", "Valuation offers reasonable upside with balanced risks." ], "target_price_6m": 95, "target_price_12m": 99 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 382, "createdAt": "2026-04-09T05:21:46.491Z", "usage": { "inputTokens": 2098, "outputTokens": 3598, "costUsd": 0.002099 } }, { "id": "cmnr152bk0639p658u6ul2nh3", "runId": "cmnr152bi0636p658t138gcz0", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\"model\":\"Equity-Research-Alpha-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"RVTY\",\"currency\":\"USD\",\"current_price\":90.4,\"target_price_6m\":98,\"target_price_12m\":105,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Forward P/E of 18x offers an attractive entry point for a high-margin life sciences asset.\",\"Biopharma destocking headwinds are moderating, setting up a potential revenue growth inflection.\",\"Strong gross margins of 60% provide a solid foundation for operating leverage as volumes recover.\",\"Exposure to high-growth cell and gene therapy markets supports long-term structural demand.\",\"Near-term risks remain tied to biotech funding constraints and sluggish capital equipment spending.\"],\"key_drivers\":[{\"driver\":\"Biotech funding environment\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pharma destocking trends\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Cell and gene therapy adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Capital equipment spending\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Interest rate stabilization\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Prolonged downturn in early-stage biotech funding.\",\"Intense competition in the life sciences tools and diagnostics markets.\",\"Slower-than-expected realization of cost synergies from recent restructuring.\",\"Macroeconomic pressures delaying large capital equipment purchases by pharma clients.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.25,\"wacc\":0.085,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":72,\"prob\":0.25,\"notes\":\"Prolonged biopharma destocking and funding drought compress multiples.\"},\"base\":{\"target_price\":105,\"prob\":0.55,\"notes\":\"Gradual end-market recovery and steady margin expansion drive earnings growth.\"},\"bull\":{\"target_price\":121,\"prob\":0.2,\"notes\":\"Rapid cell and gene therapy growth leads to strong earnings beats and multiple expansion.\"}},\"method_notes\":\"Valuation based on a blend of 20x forward P/E and DCF (8.5% WACC). The BUY rating reflects a 16% upside to our $105 12M target as biopharma end-markets normalize. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Equity-Research-Alpha-v1", "risks": [ "Prolonged downturn in early-stage biotech funding.", "Intense competition in the life sciences tools and diagnostics markets.", "Slower-than-expected realization of cost synergies from recent restructuring.", "Macroeconomic pressures delaying large capital equipment purchases by pharma clients." ], "ticker": "RVTY", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual end-market recovery and steady margin expansion drive earnings growth.", "target_price": 105 }, "bear": { "prob": 0.25, "notes": "Prolonged biopharma destocking and funding drought compress multiples.", "target_price": 72 }, "bull": { "prob": 0.2, "notes": "Rapid cell and gene therapy growth leads to strong earnings beats and multiple expansion.", "target_price": 121 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Biotech funding environment", "impact": "HIGH", "direction": "POS" }, { "driver": "Pharma destocking trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cell and gene therapy adoption", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Capital equipment spending", "impact": "MED", "direction": "NEG" }, { "driver": "Interest rate stabilization", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 20x forward P/E and DCF (8.5% WACC). The BUY rating reflects a 16% upside to our $105 12M target as biopharma end-markets normalize. Not investment advice.", "current_price": 90.4, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 18x offers an attractive entry point for a high-margin life sciences asset.", "Biopharma destocking headwinds are moderating, setting up a potential revenue growth inflection.", "Strong gross margins of 60% provide a solid foundation for operating leverage as volumes recover.", "Exposure to high-growth cell and gene therapy markets supports long-term structural demand.", "Near-term risks remain tied to biotech funding constraints and sluggish capital equipment spending." ], "target_price_6m": 98, "target_price_12m": 105 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26076, "createdAt": "2026-04-09T05:21:46.491Z", "usage": { "inputTokens": 2445, "outputTokens": 560, "costUsd": 0.01161 } }, { "id": "cmnr152bk0637p658yd4lmgpp", "runId": "cmnr152bi0636p658t138gcz0", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI Equity Model v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"RVTY\",\"currency\":\"USD\",\"current_price\":90.4,\"target_price_6m\":93.5,\"target_price_12m\":95.5,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"Diagnostics and life-science tools franchise supports resilient recurring demand.\",\"Recent revenue growth is modest and EPS declined, tempering near-term enthusiasm.\",\"High gross and operating margins provide earnings recovery optionality.\",\"Forward multiple seems reasonable, but EV/EBITDA remains above many slower-growth peers.\",\"Balance of quality, leverage, and valuation supports a neutral outlook.\"],\"key_drivers\":[{\"driver\":\"Diagnostics demand normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring reagent/service mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin recovery from mix/pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma customer spending\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Academic/government budgets\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Valuation multiple compression\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and interest burden\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Portfolio execution and integration\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Biopharma spending remains soft longer than expected.\",\"Free-cash-flow conversion stays weak despite solid EBITDA.\",\"Acquisition integration or restructuring execution disappoints.\",\"Regulatory or reimbursement changes hurt diagnostics demand.\",\"Higher rates or deleveraging needs limit valuation expansion.\"],\"assumptions\":{\"revenue_cagr_3y\":5,\"ebit_margin_target\":24,\"wacc\":8.7,\"terminal_multiple\":15},\"scenarios\":{\"bear\":{\"target_price\":78,\"prob\":0.25,\"notes\":\"Demand stays sluggish and valuation compresses on weak cash conversion.\"},\"base\":{\"target_price\":95.5,\"prob\":0.5,\"notes\":\"Modest growth and slight margin improvement support limited upside.\"},\"bull\":{\"target_price\":112,\"prob\":0.25,\"notes\":\"Biopharma recovery and stronger margins drive rerating.\"}},\"method_notes\":\"Anchored on snapshot data and a blended forward P/E and EV/EBITDA framework using assumed mid-single-digit growth and modest margin recovery. Snapshot quote fields were kept authoritative; no sell-side targets used. ~5.6% 12M upside implies HOLD. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI Equity Model v2", "risks": [ "Biopharma spending remains soft longer than expected.", "Free-cash-flow conversion stays weak despite solid EBITDA.", "Acquisition integration or restructuring execution disappoints.", "Regulatory or reimbursement changes hurt diagnostics demand.", "Higher rates or deleveraging needs limit valuation expansion." ], "ticker": "RVTY", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest growth and slight margin improvement support limited upside.", "target_price": 95.5 }, "bear": { "prob": 0.25, "notes": "Demand stays sluggish and valuation compresses on weak cash conversion.", "target_price": 78 }, "bull": { "prob": 0.25, "notes": "Biopharma recovery and stronger margins drive rerating.", "target_price": 112 } }, "confidence": 0.64, "assumptions": { "wacc": 8.7, "revenue_cagr_3y": 5, "terminal_multiple": 15, "ebit_margin_target": 24 }, "key_drivers": [ { "driver": "Diagnostics demand normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring reagent/service mix", "impact": "MED", "direction": "POS" }, { "driver": "Margin recovery from mix/pricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Biopharma customer spending", "impact": "HIGH", "direction": "POS" }, { "driver": "Academic/government budgets", "impact": "MED", "direction": "NEG" }, { "driver": "Valuation multiple compression", "impact": "HIGH", "direction": "NEG" }, { "driver": "Leverage and interest burden", "impact": "MED", "direction": "NEG" }, { "driver": "Portfolio execution and integration", "impact": "MED", "direction": "POS" } ], "method_notes": "Anchored on snapshot data and a blended forward P/E and EV/EBITDA framework using assumed mid-single-digit growth and modest margin recovery. Snapshot quote fields were kept authoritative; no sell-side targets used. ~5.6% 12M upside implies HOLD. not investment advice", "current_price": 90.4, "recommendation": "HOLD", "thesis_bullets": [ "Diagnostics and life-science tools franchise supports resilient recurring demand.", "Recent revenue growth is modest and EPS declined, tempering near-term enthusiasm.", "High gross and operating margins provide earnings recovery optionality.", "Forward multiple seems reasonable, but EV/EBITDA remains above many slower-growth peers.", "Balance of quality, leverage, and valuation supports a neutral outlook." ], "target_price_6m": 93.5, "target_price_12m": 95.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_06335fd42d55f5710069d75d1d7814819794751bf946da7e69", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 36385, "createdAt": "2026-04-09T05:21:46.491Z", "usage": { "inputTokens": 2370, "outputTokens": 2086, "costUsd": 0.033351 } }, { "id": "cmnr152bk063ap658wg4edv4s", "runId": "cmnr152bi0636p658t138gcz0", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"RVTY\",\n \"currency\": \"USD\",\n \"current_price\": 90.4,\n \"target_price_6m\": 92.5,\n \"target_price_12m\": 95,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.58,\n \"thesis_bullets\": [\n \"Modest revenue growth persists in life sciences\",\n \"Forward PE attractive versus expected recovery\",\n \"Strong niche in cell and gene therapy tools\",\n \"Elevated debt raises balance sheet concerns\",\n \"Mixed EPS trends limit near-term momentum\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Diagnostics and therapy demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Revenue CAGR trajectory\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt servicing costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"R&D budget fluctuations\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Sector innovation pace\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration success\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Pharma R&D spending slowdown\",\n \"Higher interest on debt load\",\n \"Regulatory delays in approvals\",\n \"Supply chain and FX volatility\",\n \"Intensifying competitor pressure\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 73,\n \"prob\": 0.35,\n \"notes\": \"Prolonged R&D funding drought hurts growth.\"\n },\n \"base\": {\n \"target_price\": 95,\n \"prob\": 0.45,\n \"notes\": \"Steady 5% growth and margin gains realized.\"\n },\n \"bull\": {\n \"target_price\": 122,\n \"prob\": 0.2,\n \"notes\": \"Rapid cell/gene therapy adoption drives upside.\"\n }\n },\n \"method_notes\": \"DCF with 5% rev CAGR, 25% EBIT target, 9% WACC, 15x terminal. Mixed growth, high TTM valuation vs forward PE support HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Valuation Model", "risks": [ "Pharma R&D spending slowdown", "Higher interest on debt load", "Regulatory delays in approvals", "Supply chain and FX volatility", "Intensifying competitor pressure" ], "ticker": "RVTY", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Steady 5% growth and margin gains realized.", "target_price": 95 }, "bear": { "prob": 0.35, "notes": "Prolonged R&D funding drought hurts growth.", "target_price": 73 }, "bull": { "prob": 0.2, "notes": "Rapid cell/gene therapy adoption drives upside.", "target_price": 122 } }, "confidence": 0.58, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 15, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Diagnostics and therapy demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue CAGR trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "EBIT margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Debt servicing costs", "impact": "MED", "direction": "NEG" }, { "driver": "R&D budget fluctuations", "impact": "HIGH", "direction": "NEG" }, { "driver": "Sector innovation pace", "impact": "MED", "direction": "POS" }, { "driver": "Competitive intensity", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration success", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF with 5% rev CAGR, 25% EBIT target, 9% WACC, 15x terminal. Mixed growth, high TTM valuation vs forward PE support HOLD. Not investment advice.", "current_price": 90.4, "recommendation": "HOLD", "thesis_bullets": [ "Modest revenue growth persists in life sciences", "Forward PE attractive versus expected recovery", "Strong niche in cell and gene therapy tools", "Elevated debt raises balance sheet concerns", "Mixed EPS trends limit near-term momentum" ], "target_price_6m": 92.5, "target_price_12m": 95 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "d1ec348f-f74e-99e1-80dc-c178a72028d9", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 15198, "createdAt": "2026-04-09T05:21:46.491Z", "usage": { "inputTokens": 2710, "outputTokens": 2711, "costUsd": 0.048795 } } ] } }